These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

71 related items for PubMed ID: 15251132

  • 1. Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation.
    Dinarello CA.
    Curr Opin Pharmacol; 2004 Aug; 4(4):378-85. PubMed ID: 15251132
    [Abstract] [Full Text] [Related]

  • 2. Surface-bound anti-type II collagen-containing immune complexes induce production of tumor necrosis factor alpha, interleukin-1beta, and interleukin-8 from peripheral blood monocytes via Fc gamma receptor IIA: a potential pathophysiologic mechanism for humoral anti-type II collagen immunity in arthritis.
    Mullazehi M, Mathsson L, Lampa J, Rönnelid J.
    Arthritis Rheum; 2006 Jun; 54(6):1759-71. PubMed ID: 16736518
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Reduction of inflammation by decreasing production of interleukin-1 or by specific receptor antagonism.
    Dinarello CA.
    Int J Tissue React; 1992 Jun; 14(2):65-75. PubMed ID: 1399323
    [Abstract] [Full Text] [Related]

  • 5. Interleukin-1beta influences the effect of infliximab on temporomandibular joint pain in rheumatoid arthritis.
    Kopp S, Alstergren P, Ernestam S, Nordahl S, Bratt J.
    Scand J Rheumatol; 2006 Jun; 35(3):182-8. PubMed ID: 16766364
    [Abstract] [Full Text] [Related]

  • 6. [Biological modulation of IL-1 activity: role and development of its natural inhibitor IL-1Ra].
    Dayer JM.
    Reumatismo; 2004 Jun; 56(1 Suppl 1):3-8. PubMed ID: 15201935
    [Abstract] [Full Text] [Related]

  • 7. Interleukin-1 drives pathogenic Th17 cells during spontaneous arthritis in interleukin-1 receptor antagonist-deficient mice.
    Koenders MI, Devesa I, Marijnissen RJ, Abdollahi-Roodsaz S, Boots AM, Walgreen B, di Padova FE, Nicklin MJ, Joosten LA, van den Berg WB.
    Arthritis Rheum; 2008 Nov; 58(11):3461-70. PubMed ID: 18975337
    [Abstract] [Full Text] [Related]

  • 8. The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis.
    Dayer JM.
    Rheumatology (Oxford); 2003 May; 42 Suppl 2():ii3-10. PubMed ID: 12817089
    [Abstract] [Full Text] [Related]

  • 9. Is IL-1 a good therapeutic target in the treatment of arthritis?
    Burger D, Dayer JM, Palmer G, Gabay C.
    Best Pract Res Clin Rheumatol; 2006 Oct; 20(5):879-96. PubMed ID: 16980212
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Soluble interleukin-1 receptor accessory protein ameliorates collagen-induced arthritis by a different mode of action from that of interleukin-1 receptor antagonist.
    Smeets RL, Joosten LA, Arntz OJ, Bennink MB, Takahashi N, Carlsen H, Martin MU, van den Berg WB, van de Loo FA.
    Arthritis Rheum; 2005 Jul; 52(7):2202-11. PubMed ID: 15986350
    [Abstract] [Full Text] [Related]

  • 12. Activation of the peroxisome proliferator-activated receptor alpha pathway potentiates interleukin-1 receptor antagonist production in cytokine-treated chondrocytes.
    François M, Richette P, Tsagris L, Fitting C, Lemay C, Benallaoua M, Tahiri K, Corvol MT.
    Arthritis Rheum; 2006 Apr; 54(4):1233-45. PubMed ID: 16572457
    [Abstract] [Full Text] [Related]

  • 13. Analysis of tumor necrosis factor-alpha, interleukin-6, interleukin-1beta, soluble tumor necrosis factor receptors I and II, interleukin-6 soluble receptor, interleukin-1 soluble receptor type II, interleukin-1 receptor antagonist, and protein in the synovial fluid of patients with temporomandibular joint disorders.
    Kaneyama K, Segami N, Sun W, Sato J, Fujimura K.
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2005 Mar; 99(3):276-84. PubMed ID: 15716832
    [Abstract] [Full Text] [Related]

  • 14. Interleukin-18 and the pathogenesis of inflammatory diseases.
    Dinarello CA.
    Semin Nephrol; 2007 Jan; 27(1):98-114. PubMed ID: 17336692
    [Abstract] [Full Text] [Related]

  • 15. Adenoviral delivery of IL-1 receptor antagonist abrogates disease activity during the development of autoimmune arthritis in IL-1 receptor antagonist-deficient mice.
    Hur W, Cho ML, Yoon SK, Kim SY, Ju JH, Jhun JY, Heo SB, Moon YM, Min SY, Park SH, Kim HY.
    Immunol Lett; 2006 Aug 15; 106(2):154-62. PubMed ID: 16793145
    [Abstract] [Full Text] [Related]

  • 16. Outside-to-inside signaling through transmembrane tumor necrosis factor reverses pathologic interleukin-1beta production and deficient apoptosis of rheumatoid arthritis monocytes.
    Meusch U, Rossol M, Baerwald C, Hauschildt S, Wagner U.
    Arthritis Rheum; 2009 Sep 15; 60(9):2612-21. PubMed ID: 19714631
    [Abstract] [Full Text] [Related]

  • 17. Collagen-induced arthritis in mice: a major role for tumor necrosis factor-alpha.
    Williams RO.
    Methods Mol Biol; 2007 Sep 15; 361():265-84. PubMed ID: 17172717
    [Abstract] [Full Text] [Related]

  • 18. Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis.
    Spohn G, Keller I, Beck M, Grest P, Jennings GT, Bachmann MF.
    Eur J Immunol; 2008 Mar 15; 38(3):877-87. PubMed ID: 18253928
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.